HasenTech

HasenTech

Richard Goldsby, PhD
CEO
Thomas B. Walton Professor of Biology Emeritus, Amherst College

Barbara Osborne, PhD
PI, Professor, UMass Amherst, Veterinary & Animal Science, Chair of SAB

Katherine Knight, PhD
PI, Professor, Chair of Microbiology and Immunology, Loyola University Chicago
Contact Us

hasentech@hasentechllc.com

www.hasentechbio.com

 

A Novel Cell-Based Therapy for Graft-Versus-Host Disease

HasenTech is focused on providing tools for preventing and treating Graft-Versus-Host Disease.

Graft versus host disease (GVHD) is an often lethal complication from allogeneic hematopoietic stem cell transplantation used as treatment for a variety of hematologic malignancies. GVHD results from an attack on host cells by alloreactive T cells of the donor. Standard prevention and treatment for GVHD is administration of broadly immunosuppressive drugs, which suppress alloreactive T cells. These treatments however, have as a side-effect, increased risk for infection.

The technology develops a protocol whereby an exopolysaccharide (EPS) purified from a commensal soil bacterium, Bacillus subtilis induces anti-inflammatory myeloid cells, which inhibit activation of T cells.

Associated Facility / Faculty / Staff
    • Professor Emeritus of Veterinary and Animal Sciences 

    Barbara Osborne

    Department of Veterinary and Animal Sciences
    427F Integrated Sciences Building
    660 North Pleasant Street
    Amherst, MA 01003

    (413) 545-4882
    osborne@vasci.umass.edu
    www.umass.edu/veterinary-animal-sciences/about/directory/barbara-osborne

    • Startups